Saudi Retrospective Study Compares Favipiravir & Hydroxychloroquine

Saudi Retrospective Study Compares Favipiravir & Hydroxychloroquine

Recently, a group of Saudi Arabian researchers from King Abdulaziz University and other academic medical centers in the nation investigated both Hydroxychloroquine (HCQ) and Favipiravir as possible COVID-19 treatments. Both drugs are used in many countries, including Saudi Arabia, during the pandemic for early-onset SARS-CoV-2 infection. Seeking to compare the effectiveness and safety of the two drugs, the investigational team, led by Aziza Al-Rafiah, conducted a retrospective cohort study evaluating the drugs’ impact on 508 patients admitted to King Faisal Medical Complex in Tarif, Saudi Arabia, from June 2020 to August 2020. The study authors indicate that both HCQ and Favipiravir appear to decrease mortality and need for oxygen, but a retrospective study such as this one has limitations. The safety signal for HCQ was stronger.

Background

During the first part of the pandemic in Saudi Arabia, health systems needed a rapid response, leveraging treatments that were thought to provide some benefit, including both HCQ and Favipiravir. Health care professionals used these treatments without collecting baseline data, from C-reactive protein (CRP) to D-dimer and lymphoc...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee